A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Abroad (travel likely)RecruitingPHASE2

Conditions

Neoplasms, Endometrial

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

GSK Investigational Site, Jinan, Shandong, China
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718
Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466
Contact: Principal Investigator (Dapeng Li)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

Advanced NSCLC · Advanced Endometrial Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Baoding, China · Harbin, China

SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

Endometrial Cancer Stage I · Mmr Deficiency · Endometrioid Endometrial Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Sydney, Australia · Brisbane, Australia

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Advanced Endometrial Carcinoma · Advanced Head and Neck Squamous Cell Carcinoma · Advanced Malignant Solid Neoplasm

Abroad (travel likely)RecruitingPHASE1

Houston, United States